LLY Form 4: Director Kimberly Johnson acquires Eli Lilly stock
Rhea-AI Filing Summary
Eli Lilly and Company director Kimberly H. Johnson reported buying 215.327 shares of Eli Lilly common stock on 11/17/2025. The Form 4 shows the shares were acquired at a price of $1,021.7 per share. After this transaction, she beneficially owns a total of 3,264.731 shares of Eli Lilly common stock directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 215.327 | $1,021.70 | $220K |
FAQ
What insider transaction did Eli Lilly (LLY) report in this Form 4?
The Form 4 reports that director Kimberly H. Johnson acquired 215.327 shares of Eli Lilly common stock on 11/17/2025 at a price of $1,021.7 per share.
What is the role of the reporting person in Eli Lilly (LLY)?
The reporting person, Kimberly H. Johnson, is identified as a Director of Eli Lilly and Company.
Was this Eli Lilly (LLY) insider filing made by a single reporting person?
Yes. The filing indicates that the Form 4 was filed by one reporting person, not by a group.
What type of securities were involved in this Eli Lilly (LLY) Form 4?
The transaction involved non-derivative securities, specifically Eli Lilly common stock. The table for derivative securities shows no reportable derivative positions in this excerpt.
What is the transaction code for the Eli Lilly (LLY) insider purchase?
The Form 4 lists the transaction in Table I with code A, indicating acquired shares of Eli Lilly common stock.
AI-generated analysis. How Rhea-AI works. Not financial advice.